article thumbnail

Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

PharmaShots

Only patients with qualifying average daily pain scores (ADPS) of 5-9, and who were diary and medication compliant were eligible to move into the 6-week double-blind treatment period. The purpose of the single-blind run in was to minimize patients who might be suboptimal in diary and medication compliance.